Santen Readies India Expansion Via Centaur Alliance
Japan’s Santen appears set for a scale up in India via an alliance with Centaur Pharmaceuticals. The partners outline to Scrip the broad contours of the India plan.
You may also be interested in...
Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.
India’s prime minister has declared that doctors should prescribe medicines using only non-proprietary generic names in an effort to reduce medical bills, but the medical fraternity says the move could jeopardize patient safety, while hurdles mean others see only limited pharma industry impact in the short term.
Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.